Table: Taisho Pharmaceutical HD -9-MTH group results
Feb 2 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2016 Dec 31, 2015 Mar 31, 2017
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 216.43 224.98 281.50
(-3.8 pct) (+1.5 pct) (-3.0 pct)
Operating 26.56 22.72 30.50
(+16.9 pct) (-8.5 pct) (+5.6 pct)
Recurring 31.38 29.10 36.50
(+7.8 pct) (-5.8 pct) (-0.7 pct)
Net 23.67 18.71 27.50
(+26.5 pct) (-4.8 pct) (+22.4 pct)
EPS 296.21 yen 230.74 yen 344.15 yen
EPS Diluted 296.01 yen 230.61 yen
Ann Div 100.00 yen 110.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
((Tokyo Headline News Desk +813 6441 1812))
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10